Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Receivables (2021 - 2023)

Inhibikase Therapeutics (IKT) has disclosed Receivables for 3 consecutive years, with $79604.0 as the latest value for Q2 2023.

  • On a quarterly basis, Receivables rose 1114.96% to $79604.0 in Q2 2023 year-over-year; TTM through Jun 2023 was $79604.0, a 1114.96% increase, with the full-year FY2022 number at $39881.0, down 63.79% from a year prior.
  • Receivables was $79604.0 for Q2 2023 at Inhibikase Therapeutics, up from $64521.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $110141.0 in Q4 2021 to a low of $6552.0 in Q2 2022.
  • A 3-year average of $51788.1 and a median of $47976.0 in 2022 define the central range for Receivables.
  • Peak YoY movement for Receivables: plummeted 63.79% in 2022, then soared 1114.96% in 2023.
  • Inhibikase Therapeutics' Receivables stood at $110141.0 in 2021, then tumbled by 63.79% to $39881.0 in 2022, then surged by 99.6% to $79604.0 in 2023.
  • Per Business Quant, the three most recent readings for IKT's Receivables are $79604.0 (Q2 2023), $64521.0 (Q1 2023), and $39881.0 (Q4 2022).